Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Zippia finds jobs where you're a top candidate and applies on your behalf.
TELA Bio's peak revenue was $69.3M in 2024. The peak quarterly revenue was $19.0M in 2024(q3).
TELA Bio's revenue increased from $8.3m in 2018 to $69.3M currently. That's a 737.56% change in annual revenue.
| Fiscal year / year | TELA Bio revenue |
|---|---|
| 2018 | $8.3M |
| 2019 | $15.4M |
| 2020 | $18.2M |
| 2021 | $29.5M |
| 2022 | $41.4M |
| 2023 | $58.5M |
| 2024 | $69.3M |
Rate TELA Bio's financial transparency
TELA Bio saw the greatest revenue growth in 2019, when revenue increased by 86.68%.
TELA Bio had the lowest revenue growth in 2020, when revenue changed by 17.91%.
| Year | TELA Bio growth |
|---|---|
| 2019 | 87%↑ |
| 2020 | 18%↑ |
| 2021 | 62%↑ |
| 2022 | 41%↑ |
| 2023 | 41%↑ |
| 2024 | 19%↑ |
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | - | - | $4.0M | $4.9M |
| 2020 | $3.7M | $3.5M | $5.3M | $5.7M |
| 2021 | $5.9M | $7.6M | $7.7M | $8.4M |
| 2022 | $8.2M | $10.4M | $11.2M | $11.6M |
| 2023 | $11.9M | $14.5M | $15.1M | $17.0M |
| 2024 | $16.6M | $16.1M | $19.0M | $17.6M |
Do you work at TELA Bio?
Is TELA Bio transparent about its revenue structure?
| CEO | Antony Koblish |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 108 |
| Date Founded | 2012 |
| Headquarters | Malvern, Pennsylvania |
| Number of Locations | 1 |
| Revenue | $69.3M |
| Net Income | -$44,296,000 |
| Gross Proft | $46.9M (2024) |
| EBITDA | ($32.3M) (2024) |
| Tax Rate | 0.0% |
| Total Assets | $67,855,000 |
| Ticker | TELA |
TELA Bio received early financing of $6.0M on 2013-08-14.
| Series | Round size | Date |
|---|---|---|
| Private Equity | $6M | 08/2013 |
| Series Unknown | $45.4M | 10/2014 |
| Series Unknown | $500K | 11/2014 |
| Series Unknown | $7.4M | 01/2017 |
| Series Unknown | $25M | 10/2017 |
| Series Unknown | $1M | 03/2018 |
| Series Unknown | $2M | 11/2018 |
| Post Ipo Equity | $48M | 06/2020 |
| Investors | Security type |
|---|---|
| Pacira Pharmaceuticals Inc | Series Unknown |
| OrbiMed Advisors | Series Unknown |
| Quaker Partners | Series Unknown |
| Signet Healthcare Partners | Series Unknown |
| ProMedica Health System Inc | Series Unknown |
Zippia gives an in-depth look into the details of TELA Bio, including salaries, political affiliations, employee data, and more, in order to inform job seekers about TELA Bio. The employee data is based on information from people who have self-reported their past or current employments at TELA Bio. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by TELA Bio. The data presented on this page does not represent the view of TELA Bio and its employees or that of Zippia.
TELA Bio may also be known as or be related to TELA BIO, INC., TELA Bio, TELA Bio Inc, TELA Bio, Inc. and Tela Bio, Inc.